Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment that Mologic Ltd have requested for Porton Down to evaluate
Tavistock Investment (TAVI.L) Strategic partnership with Titan Wealth & disposal
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation. With the publication of
Omega Diagnostics Gp (ODX.L) Regulatory progress for VISITECT® COVID-19 test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, provides the following update on VISITECT® COVID-19 Antigen test regulatory approvals.
Omega Diagnostics Gp (ODX.L) Progress update
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, provides the following update on its UK Government manufacturing contract.
Omega Diagnostics Gp (ODX.L) Positive data for COVID-19 antigen test
Positive study data for Mologic COVID-19 lateral flow antigen test
Omega Diagnostics Gp (ODX.L) Positive data for Mologic COVID-19 antigen test
Further positive data for Mologic COVID-19 lateral flow antigen test
Omega Diagnostics Gp (ODX.L) Launch of VISITECT® COVID-19 Antigen & Update
Rapid diagnostic test for visual detection of SARS-CoV-2 antigen
Omega Diagnostics Gp (ODX.L) CE-Mark: Mologic COVID19 lateral flow antigen test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has CE-Marked Mologic Ltd’s (‘Mologic’) lateral flow antigen test for COVID-19, to
Omega Diagnostics Gp (ODX.L) UK Public Sector Contract disclosure
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that a UK Public Sector contract disclosure has been published yesterday in relation to
Omega Diagnostics Gp (ODX.L) Contract with Screen4
Contract with Screen4 for COVID-19 antibody laboratory-based testing service
Omega Diagnostics Gp (ODX.L) UK-RTC statement on AbC-19TM rapid antibody test
Lateral flow test data shows potential for companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine
Omega Diagnostics Gp (ODX.L) AbC-19TM rapid antibody test performance data
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes